17.8 C
New York
Tuesday, June 9, 2026

Tag: epilepsy

Lennox-Gastaut Syndrome (LGS) Foundation Launches Pre-Competitive Research Accelerator for LGS and Associated Developmental and Epileptic Encephalopathies

SAN DIEGO, June 8, 2026 /PRNewswire/ -- The Lennox-Gastaut Syndrome (LGS) Foundation today announced the launch of the LGS and Associated DEE Research Accelerator,...

Praxis Precision Medicines Provides Vormatrigine Program Update

POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure

Global Digital Health Market Poised for Robust Growth at a CAGR of ~18% by 2032 Amid Rising Demand for Remote Care| DelveInsight

The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable devices, and AI-powered health solutions. Rising healthcare costs and...

Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial

During Sleep Health Week (11-15 August 2025), Australians living with insomnia are reminded that a new treatment is on the horizon – with clinical...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Piper Sandler senior research analyst Yasmin Rahini on August 7, 2025 at 11:00amEST.

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST.

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Medical Cannabis Market Report 2025-2033 | Rising Clinical Trials, R&D Activities, and Commercialization of Cannabis-based Indications

Global medical cannabis market to hit USD 68.6 billion by 2033, growing at a 7.1% CAGR. Key growth drivers include increasing legalization and therapeutic use for conditions like chronic pain and epilepsy. North America leads due to progressive regulations. Top players like Canopy Growth and GW Pharmaceuticals drive innovation in the sector.
Global medical cannabis market to hit USD 68.6 billion by 2033, growing at a 7.1% CAGR. Key growth drivers include increasing legalization and therapeutic use for conditions like chronic pain and epilepsy. North America leads due to progressive regulations. Top players like Canopy Growth and GW Pharmaceuticals drive innovation in the sector.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEpilepsy